重組人胰島素市場：依產品類型、品牌名稱、通路及地區分類

Human Recombinant Insulin Market, By Product Type, By Brand, By Distribution Channel, By Geography

出版日期: 2026年02月12日 | 出版商:

Coherent Market Insights | 英文 151 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

2026年重組人胰島素市場規模估計為365億美元，預計2033年將達到601億美元。預計2026年至2033年，其複合年成長率將達7.4%。

分析範圍		分析詳情
基準年	2025	市場規模（2026 年）	365億美元
效能數據	2020-2024	預測期	2026-2033
預測期（2026-2032 年）複合年成長率	7.40%	預計金額（2033 年）	601億美元

重組人類胰島素是一種合成胰島素，它是利用重組DNA技術在大腸桿菌中培養胰島素蛋白質而製成的。與其他類型的胰島素（例如豬胰島素或牛胰島素）相比，重組人類胰島素起效更快，免疫抗原性更低。人類胰島素主要有兩種劑型：短效（常規）和中效（NPH）。此外，預混合料人類胰島素結合了兩種胰島素，其中一種用於全天控制血糖值，另一種用於餐後控制血糖值。由於全球範圍內胰島素生物相似藥（後續產品）的開發，重組人類胰島素市場正在蓬勃發展。

市場動態

久坐的生活方式、不健康的飲食習慣、肥胖、葡萄糖耐受不良、糖尿病家族病史以及胰島素阻抗增加是全球人群中糖尿病的一些風險因素。此外，糖尿病患者人數的不斷增加以及重組人類胰島素研發投入的活性化，預計將在不久的將來推動重組人類胰島素市場的成長。領先的生產商正在向市場推出創新且改良的重組人胰島素，以滿足日益成長的胰島素需求。例如，2021年11月16日，製藥公司Viatris Inc.和兒童公司Biocon Biologics Ltd.宣佈在美國推出品牌相容生物類似藥「SEMGLEE（甘精胰島素-yfgn）注射液」和非品牌產品甘精胰島素（甘精胰島素-yfgn）注射液，旨在幫助1型糖尿病成人和成人兒童患者以及2型糖尿病這些藥物有助於控制第1型糖尿病成人和兒童患者以及第2型糖尿病成人患者的高血糖。兩種生物相似藥均有管瓶和預填充注射筆兩種劑型。

本報告的主要特點

本報告對全球重組人類胰島素市場進行了詳細分析，包括市場規模（以十億美元計）和預測期（2026-2033 年）的複合年成長率，以 2025 年為基準年。
此外，它還確定了每個細分市場的潛在商機，並描述了該市場中一系列有吸引力的投資提案。
此外，它還提供了有關市場促進因素和限制因素、機會、新產品發布和核准、市場趨勢、區域展望以及主要企業採取的競爭策略的重要見解。
本文檔根據以下參數介紹了全球重組人胰島素市場主要企業的概況：公司概況、產品系列、主要亮點、財務表現和策略。
本報告中的見解將使負責人和企業經營團隊能夠就未來的產品發布、產品線更新、市場擴張和行銷策略做出明智的決策。
《全球重組人胰島素市場》報告面向該行業的各種相關人員，包括投資者、供應商、產品製造商、經銷商、新進業者和金融分析師。
相關人員可以透過分析全球重組人類胰島素市場中使用的各種策略矩陣來促進決策。

北美洲
- 美國
- 加拿大
拉丁美洲
- 巴西
- 阿根廷
- 墨西哥
- 其他拉丁美洲
歐洲
- 德國
- 英國
- 西班牙
- 法國
- 義大利
- 俄羅斯
- 其他歐洲國家
亞太地區
- 中國
- 印度
- 日本
- 澳洲
- 韓國
- ASEAN
- 亞太其他地區
中東
- 海灣合作理事會國家
- 以色列
- 其他中東國家
非洲
- 南非
- 北非
- 中非

第8章競爭情勢

Novo Nordisk A/S
Eli Lilly and Company
Sanofi SA
Julphar Gulf Pharmaceutical Industries
Biocon Limited
Bioton SA
Gan &Lee Pharmaceuticals, Ltd.
Zhuhai United Laboratories Co., Ltd.
Wanbang Biopharmaceuticals Co., Ltd.
Dongbao Enterprise Group Co., Ltd.

第9章分析師建議

機會
分析師意見
Coherent Opportunity Map (COM)

第10章：參考文獻與分析方法

參考
分析方法
關於 Coherent Market Insights

簡介目錄

Product Code: CMI1797

Human Recombinant Insulin Market is estimated to be valued at USD 36.5 Bn in 2026 and is expected to reach USD 60.1 Bn by 2033, growing at a compound annual growth rate (CAGR) of 7.4% from 2026 to 2033.

Report Coverage		Report Details
Base Year:	2025	Market Size in 2026:	USD 36.5 Bn
Historical Data for:	2020 To 2024	Forecast Period:	2026 To 2033
Forecast Period 2026 to 2033 CAGR:	7.40%	2033 Value Projection:	USD 60.1 Bn

Recombinant human insulin is the synthetic insulin, developed using recombinant DNA technology by growing insulin proteins within Escherichia coli. Recombinant human insulin has a faster onset of action and lower immunogenicity than other types of insulin such as pork or beef insulin. Human insulin is available primarily in two forms: a short acting (regular) form and an intermediate acting (NPH) form. Moreover, the premixed human insulin is formed by combining two types of insulin, among which one is controls blood sugar level throughout the day, while second type of insulin helps to control blood sugar at meal times. Human recombinant insulin market is gaining traction due to development of biosimilars analogue of insulin, worldwide.

Market Dynamics

Sedentary and unhealthy lifestyle, unhealthy eating, obesity, impaired glucose tolerance, diabetes family history, and increased insulin resistance are some of the risk factors for developing diabetes among the global population. Moreover, increasing number of diabetic population, and growing research and development (R&D) studies in human recombinant insulin to introduce improved version of insulin in the market is expected to boost the growth of human recombinant insulin market in near future. Key manufactures are launching innovative and improved human recombinant insulin in the market to fulfill the increasing demand for insulin. For instance, on November 16, 2021, Viatris Inc., a pharmaceutical company and Biocon Biologics Ltd., a biopharmaceutical company announced the U.S. launch of interchangeable biosimilars SEMGLEE (insulin glargine-yfgn) injection, a branded product, and Insulin Glargine (insulin glargine-yfgn) injection, an unbranded product, to help control high blood sugar in adult and pediatric patients with type 1 diabetes and adults with type 2 diabetes. Both biosimilars products are available in vial and prefilled pen.

Key features of the study

This report provides an in-depth analysis of the global human recombinant insulin market, and provides market size (USD Bn) and compound annual growth rate (CAGR%) for the forecast period (2026-2033), considering 2025 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global human recombinant insulin market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include Novo Nordisk A/S, Eli Lilly and Company, Sanofi S.A., Julphar Gulf Pharmaceutical Industries, Biocon Limited, Bioton S.A., Gan & Lee Pharmaceuticals, Ltd., Zhuhai United Laboratories Co., Ltd., Wanbang Biopharmaceuticals Co., Ltd., and Dongbao Enterprise Group Co., Ltd.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global human recombinant insulin market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global human recombinant insulin market

Market Segmentation

Product Type Insights (Revenue, USD Bn, 2026 - 2033)
- Rapid-Acting Human Insulin
- Short-Acting Human Insulin
- Intermediate-Acting Human Insulin
- Long-Acting Human Insulin
- Premixed Human Insulin
Brand Insights (Revenue, USD Bn, 2026 - 2033)
- Humalog
- Novolog
- Apidra
- Humulin R
- Novolin R
- Humulin N
- Novolin N
- Levemir
- Lantus
- Humalog Mix
- Novolog Mix
- Others
Distribution Channel Insights (Revenue, USD Bn, 2026 - 2033)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Regional Insights (Revenue, USD Bn, 2026 - 2033)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- North Africa
- Central Africa
- South Africa
Key Players Insights
- Novo Nordisk A/S
- Eli Lilly and Company
- Sanofi S.A.
- Julphar Gulf Pharmaceutical Industries
- Biocon Limited
- Bioton S.A.
- Gan & Lee Pharmaceuticals, Ltd.
- Zhuhai United Laboratories Co., Ltd.
- Wanbang Biopharmaceuticals Co., Ltd.
- Dongbao Enterprise Group Co., Ltd.

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Overview

Report Description
- Market Definition and Scope
Executive Summary
- Global Human Recombinant Insulin Market, By Product Type
- Global Human Recombinant Insulin Market, By Brand
- Global Human Recombinant Insulin Market, By Distribution Channel
- Global Human Recombinant Insulin Market, By Region

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
Impact Analysis
Key Highlights
Regulatory Scenario
Product Launches/Approvals
PEST Analysis
PORTER's Analysis
Market Opportunities
Regulatory Scenario
Key Developments
Industry Trend

4. Global Human Recombinant Insulin Market, By Product Type, 2020-2033, (USD Bn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
Rapid-Acting Human Insulin
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Bn)
Short-Acting Human Insulin
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Bn)
Intermediate-Acting Human Insulin
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Bn)
Long-Acting Human Insulin
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Bn)
Premixed Human Insulin
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Bn)

5. Global Human Recombinant Insulin Market, By Brand, 2020-2033, (USD Bn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
Humalog
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Bn)
Novolog
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Bn)
Apidra
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Bn)
Humulin R
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Bn)
Novolin R
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Bn)
Humulin N
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Bn)
Novolin N
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Bn)
Levemir
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Bn)
Lantus
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Bn)
Humalog Mix
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Bn)
Novolog Mix
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Bn)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Bn)

6. Global Human Recombinant Insulin Market, By Distribution Channel, 2020-2033, (USD Bn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Bn)
Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Bn)
Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Bn)

7. Global Human Recombinant Insulin Market, By Region, 2020 - 2033, Value (USD Bn)

Introduction
- Market Share (%) Analysis, 2026, 2028 & 2033, Value (USD Bn)
- Market Y-o-Y Growth Analysis (%), 2021 - 2033, Value (USD Bn)
- Regional Trends
North America
- Introduction
- Market Size and Forecast, By Product Type, 2020 - 2033, Value (USD Bn)
- Market Size and Forecast, By Brand, 2020 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2033, Value (USD Bn)
  - U.S.
  - Canada
Latin America
- Introduction
- Value (USD Bn)
- Market Size and Forecast, By Product Type, 2020 - 2033, Value (USD Bn)
- Market Size and Forecast, By Brand, 2020 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2033, Value (USD Bn)
  - Brazil
  - Argentina
  - Mexico
  - Rest of Latin America
Europe
- Introduction
- Value (USD Bn)
- Market Size and Forecast, By Product Type, 2020 - 2033, Value (USD Bn)
- Market Size and Forecast, By Brand, 2020 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2033, Value (USD Bn)
  - Germany
  - U.K.
  - Spain
  - France
  - Italy
  - Russia
  - Rest of Europe
Asia Pacific
- Introduction
- Value (USD Bn)
- Market Size and Forecast, By Product Type, 2020 - 2033, Value (USD Bn)
- Market Size and Forecast, By Brand, 2020 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2033, Value (USD Bn)
  - China
  - India
  - Japan
  - Australia
  - South Korea
  - ASEAN
  - Rest of Asia Pacific
Middle East
- Introduction
- Value (USD Bn)
- Market Size and Forecast, By Product Type, 2020 - 2033, Value (USD Bn)
- Market Size and Forecast, By Brand, 2020 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2033, Value (USD Bn)
  - GCC Countries
  - Israel
  - Rest of Middle East
Africa
- Introduction
- Value (USD Bn)
- Market Size and Forecast, By Product Type, 2020 - 2033, Value (USD Bn)
- Market Size and Forecast, By Brand, 2020 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2033, Value (USD Bn)
  - South Africa
  - North Africa
  - Central Africa

8. Competitive Landscape

Novo Nordisk A/S
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Eli Lilly and Company
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Sanofi S.A.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Julphar Gulf Pharmaceutical Industries
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Biocon Limited
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Bioton S.A.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Gan & Lee Pharmaceuticals, Ltd.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Zhuhai United Laboratories Co., Ltd.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Wanbang Biopharmaceuticals Co., Ltd.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Dongbao Enterprise Group Co., Ltd.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies